StemCell Therapy

Since the World Health Organization declared it a pandemic in March 2020, the novel coronavirus SARS-CoV-2 has caused millions of infections and hundreds of thousands of deaths worldwide. Currently there is no cure, and many initial treatments being tested against COVID-19 were designed for other viral infections. Multiple drugmakers are scrambling to find treatments that might help fight off the coronavirus or prevent infections altogetherin a Herculean effort to collapse the typical 1015-year drug development timeline to under a year.

Antiviral human monoclonal antibodies (mAbs) are promising drug candidates for preventing or treating severe viral diseases, but the long timelineson the order of yearsneeded for antibody discovery, functional analysis, preclinical studies, and manufacturing limit their rapid deployment and use as immunotherapeutics. Vanderbilt University Medical Center researchers Robert Carnahan and Pavlo Gilchuk are part of the scientific team attempting to compress the timeline for potent antiviral antibody discovery and characterization by integrating a series of advances in single-cell messenger RNA sequence analysis, bioinformatics, synthetic biology, and high-throughput functional analysis. Their work enabled the rapid discovery of a diverse panel of highly potent antiviral human mAbs against the SARS-CoV-2 Spike protein and the validation of their activity both in vitro and in vivo. These results provide a potential framework for expedited antibody discovery programs against viral pathogens of global concern.

During the webinar, viewers will:

This webinar will last for approximately 60 minutes.

For Research Use Only. Not for use in diagnostic procedures.

Vanderbilt Vaccine CenterNashville, TN

Dr. Pavlo Gilchuk received his M.S. in biochemistry and his doctorate in biotechnology from Taras Shevchenko National University of Kyiv, Ukraine. His work there was largely focused on single-chain antibody design and discovery. From 2002 to 2009, he was employed by Phage Biotechnology Corporation in San Diego, California, where he advanced from engineer biologist to research group manager. Dr. Gilchuk also held the position of staff scientist at the Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine (Kyiv), and served as laboratory head at the State Institute of Genetic and Regenerative Medicine, Academy of Medical Sciences of Ukraine (Kyiv). Upon transitioning to the Vanderbilt University Medical Center in Nashville, Tennessee, his initial research was directed to large-scale vaccinia virusderived T cell epitope discovery, elucidation of immunological features of lung-resident memory CD8+ T cells, and development of platforms for T celltargeted mucosal vaccination. Dr. Gilchuk is now a senior staff scientist in the laboratory of James E. Crowe, Jr. at the Vanderbilt Vaccine Center (VVC) and leads antibody-discovery technology development and evolution within this large academic team. In addition, he is currently working on methods development for rapid identification of therapeutic antibodies against viral diseases (the Defense Advanced Research Projects Agency [DARPA] Pandemic Prevention Platform program).

Vanderbilt Vaccine CenterNashville, TN

Dr. Robert Carnahan is associate director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center and an associate professor in pediatrics and radiology. He has a high level of experience with monoclonal antibodies and antibody engineering. He directed the Vanderbilt Antibody and Protein Resource (VAPR) for over 10 years. The facility grew to the point of conducting an average of 150 antibody projects per year, comprising more than 70 unique Vanderbilt investigators as well as several academic and industry partners from across the country (e.g., the University of California, Los Angeles; the Fred Hutchinson Cancer Research Center; Purdue University; Kolltan Pharmaceuticals; Becton Dickinson). Both academic and industry projects focused increasingly on therapeutic targets (cancer, viral pathogens, autoimmunity, diabetes, etc.), with work in the lab ranging from discovery to preclinical activities. Dr. Carnahan has brought this focus on innovation applied to antibody generation and detailed characterization to the Crowe Lab and the Vanderbilt Vaccine Center. During this time, he has also held numerous regional and national leadership roles within the Association of Biomolecular Resource Facilities (ABRF), to develop advances in methodologies and technical standards, oversee collaborative studies, and implement training opportunities for lab directors and personnel. Furthermore, he is also a national leader in the design and implementation of Lean management systems for biological laboratories.

Science/AAASWashington, D.C.

Dr. Oberst did her undergraduate training at the University of Maryland, College Park, and her Ph.D. in Tumor Biology at Georgetown University, Washington D.C. She combined her interests in science and writing by pursuing an M.A. in Journalism from the Philip Merrill College of Journalism at the University of Maryland, College Park. Dr. Oberst joined Science/AAAS in 2016 as the Assistant Editor for Custom Publishing. Before then she worked at Nature magazine, the Howard Hughes Medical Institute, The Endocrine Society, and the National Institutes of Mental Health.

Read the original:
Racing against time: Rapid, high-throughput discovery of antibody therapeutics for SARS-CoV-2 - Science Magazine

Model suggests ACER-001, Acers taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders compared to current treatments

Anticipate submitting ACER-001 NDA in H1 2021 assuming successful completion of additional nonclinical work and long-term stability data, and subject to additional capital

NEWTON, Mass., July 08, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced data from a food effect study in healthy volunteers showing that administration of ACER-001 in a fasted state increased systemic exposure of phenylbutyrate (PBA), phenylacetate (PAA) and phenylacetylglutamine (PAGN) levels compared to fed state, and therefore based on modeling data may improve disease management in patients with urea cycle disorders (UCDs) when compared to currently approved treatments requiring administration with food.

Results from Part B of the ACER-001 bioequivalence (BE) trial in healthy volunteers (n=36) announced in February 2020 showed that ACER-001 was bioequivalent to BUPHENYL (sodium phenylbutyrate) and were within the parameters recommended by the FDAs Guidance for Industry, Statistical Approaches to Establishing Bioequivalence. The BE trial included a food effect study, which evaluated the pharmacokinetics (PK) of sodium phenylbutyrate (NaPBA) showing that administration of ACER-001 in a fasted state achieved more than two times the maximum concentration (Cmax) of PBA compared to administration of the same dose of ACER-001 in a fed state. These results are consistent with previously published data by Nakano, et al1 that evaluated PK of NaPBA in patients with progressive familial intrahepatic cholestasis, also demonstrating that administration of NaPBA in a fasted state significantly increased PBA peak plasma concentration compared to administration of NaPBA in a fed state.

Currently approved therapies for UCDs, including BUPHENYL2 and RAVICTI3 (glycerol phenylbutyrate), are required to be administered with food. BUPHENYL is required to be administered in a fed state due to its aversive odor and taste, with side effects including nausea, vomiting and headaches, which often lead to discontinuation of treatment.4 Additionally, prescribing information states that BUPHENYL food effect is unknown. RAVICTI PK and pharmacodynamic (PD) properties were determined to be indistinguishable in fed or fasted states.5 ACER-001 is uniquely formulated with its multi-particulate, taste-masked coating to allow for administration in a fasted state, while still allowing for rapid systemic release.

Based on the results from the food effect study within the ACER-001 BE trial, Acer commissioned Rosa & Co. LLC to create a PhysioPD PK model to evaluate the potential food effect on exposure, tolerability and efficacy of ACER-001 in UCDs patients. Results from this in silico model suggest that administration of ACER-001 in a fasted state required approximately 30% less PBA to achieve comparable therapeutic benefit in a fed state. In addition, the model predicted that administration of ACER-001 in a fasted state compared to administration of BUPHENYL or RAVICTI (same amounts of PBA) in their required fed states is expected to result in higher peak blood PBA, PAA and PAGN concentrations, predicting a 43% increase in urinary PAGN levels (a negative correlation between blood ammonia area under the curve and 24-hour urinary PAGN amount has been demonstrated6).

For nearly a quarter century, phenylbutyrate has been prescribed to UCD patients with food while its effect on phenylbutyrate absorption was never determined. The results of the ACER-001 food effect study, published literature and in silico modeling suggest that ACER-001 administered in a fasted state, and likely just 10 minutes prior to meals, could offer UCD patients a safe and better disease management option compared to currently approved products that are required to be taken with food, said Chris Schelling, CEO and Founder of Acer. We formulated ACER-001 to specifically improve palatability and tolerability, and we expect that this formulation should allow ACER-001 to be successfully administered without food. We look forward to discussing these findings with the FDA later in the third quarter. Schelling continued Interestingly, the increased exposure seen under fasted conditions may have benefit in other patient populations we intend to study, such as Maple Syrup Urine Disease (MSUD), where the Cmax of phenylbutyrate is the active moiety.

About UCDsUCDs are a group of disorders caused by genetic mutations that result in a deficiency in one of the six enzymes that catalyze the urea cycle, which can lead to an excess accumulation of ammonia in the bloodstream, a condition known as hyperammonemia. Acute hyperammonemia can cause lethargy, somnolence, coma, and multi-organ failure, while chronic hyperammonemia can lead to headaches, confusion, lethargy, failure to thrive, behavioral changes, and learning and cognitive deficits. Common symptoms of both acute and chronic hyperammonemia also include seizures and psychiatric symptoms.7,8

The current treatment of UCDs consists of dietary management to limit ammonia production in conjunction with medications that provide alternative pathways for the removal of ammonia from the bloodstream. Some patients may also require individual branched-chain amino acid supplementation.

Current medical treatments for UCDs include nitrogen scavengers RAVICTI and BUPHENYL in which the active pharmaceutical ingredients are glycerol phenylbutyrate (GPBA) and sodium phenylbutyrate (NaPBA), respectively. According to a 2016 study by Shchelochkov et al., published in Molecular Genetics and Metabolism Reports, while nitrogen scavenging medications can be effective in helping to manage ammonia levels in some patients with UCDs, non-compliance with treatment is common. Reasons given for non-compliance include the unpleasant taste associated with available medications, the frequency with which medication must be taken, the number of pills, and the high cost of the medication.9

About ACER-001ACER-001 is a taste-masked, immediate-release proprietary formulation of sodium phenylbutyrate developed by Acer using a microencapsulation process. ACER-001 is being developed for the treatment of various inborn errors of metabolism, including UCDs and Maple Syrup Urine Disease (MSUD). ACER-001 microparticles consist of a core center, a layer of active drug, and a taste-masking coating that quickly dissolves in the stomach, allowing taste to be neutralized while still allowing for rapid systemic release. This taste-masked formulation may result in better patient tolerability allowing for administration in a fasted state, and likely prior to a meal. Acer has been granted orphan drug designation by the FDA for the MSUD indication. ACER-001 is under clinical investigation and its safety and efficacy have not been established. There is no guarantee that this product will receive FDA approval or become commercially available for the uses being investigated.

About Acer Therapeutics Inc.Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acers pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); and osanetant for the treatment of induced Vasomotor Symptoms (iVMS) where Hormone Replacement Therapy (HRT) is likely contraindicated. Each of Acers product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit http://www.acertx.com.

References

Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, timelines, future financial position, future revenues, projected expenses, regulatory submissions, actions or approvals, cash position, liquidity, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential for our product candidates to safely and effectively treat diseases and to be approved for marketing; the commercial or market opportunity of any of our product candidates in any target indication and any territory; our ability to secure the additional capital necessary to fund the ACER-001 program; the adequacy of our capital to support our future operations and our ability to successfully initiate and complete clinical trials and regulatory submissions; the ability to protect our intellectual property rights; our strategy and business focus; and the development, expected timeline and commercial potential of any of our product candidates. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on managements current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet our business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by our intellectual property, the substantial costs and diversion of managements attention and resources which could result from pending securities litigation, risks related to the drug development and the regulatory approval process, including the timing and requirements of regulatory actions, and the impact of competitive products and technological changes. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K. You may access these documents for no charge at http://www.sec.gov.

Investor Contact:Hans VitzthumLifeSci AdvisorsPh: 617-430-7578hans@lifesciadvisors.com

Jim DeNikeAcer Therapeutics Inc.Ph: 844-902-6100jdenike@acertx.com

Continued here:
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food...

This report provides statistics on the market situation, size, regions and growth factors. Emerging Gene Therapies Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.

The research reports onEmerging Gene Therapies Marketreport gives detailed overview of factors that affect global business scope. Emerging Gene Therapies Market report shows the latest market insights with upcoming trends and breakdowns of products and services.

Get FREE PDF Sample of the report @www.reportsnreports.com/contactme=1854862

Emerging Gene Therapies Market Top Company Analysis-Sangamo TherapeuticsCRISPR TherapeuticsCasebia TherapeuticsEditas MedicineIntellia TherapeuticsHomology Medicines

and more

Emerging Gene Therapies Market provides a comprehensive overview of the emerging gene therapy market. The report discusses gene therapy and the technology behind gene editing, outlining the advantages, limitations and current evidence for the platforms under development.

The report discusses relevant clinical studies targeting specific therapeutic indications and highlights examples of current challenges within the field, with a focus on therapies that target the eye, liver, and blood.

Additionally, the report provides a background to the CRISPR patent litigation, a key factor within the gene editing company landscape.

It provides profiles of six companies developing gene editing platforms, considers the gene therapy interests of the main pharmaceutical companies, and discusses current regulatory trends in the development of gene therapies.

The report explores how emerging gene editing products will compete with established products, their relative competitive strengths, and upcoming value inflection points within the field.

Scope of Emerging Gene Therapies Market Report- What are the key emerging products within the gene therapy landscape? Which companies have the strongest pipeline of innovative products? How will gene editing disrupt existing gene therapy products? What are the regulatory trends for emerging gene therapies? What are the interests of pharmaceutical companies within the field?

Get this Report @www.reportsnreports.com/purchasme=1854862

Reasons to accessthis Report- Achieve an up-to-date understanding of the area, with a comprehensive reference of key products within the gene therapy landscape, compared across technology-specific relevant characteristics such as editing mechanism and delivery vector. Conduct competitive analysis using indication-specific, side-by-side comparisons of the latest data for key gene therapy products in the strategically relevant areas of eye, blood, and liver. Conduct strategic analysis using an overview of gene therapy specific considerations for evaluating and developing gene therapy products the CRISPR patent space, emerging regulatory trends, innovation leaders and the interests of pharma in gene therapy.

Table of Contents in this Report-1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Introduction 102.1 Gene Therapy Definitions 102.2 Report Coverage the Emerging Gene Therapy Pipeline 112.3 History of Gene Therapy 122.4 Limitations of Gene Transfer 132.5 The Development of Targeted Gene Editing 132.6 Overview of Gene Editing Platforms 132.6.1 Zinc Fingers (1996) 132.6.2 Transcription Activator-Like Effectors (2011) 142.6.3 The CRISPR/Cas System (2013) 152.6.4 Effectors for Targeting Domains 192.6.5 Comparison of Gene Editing Systems 192.6.6 Summary of Gene Editing Systems 192.7 Overview of In Vivo Gene Therapy 212.7.1 Editing is Dependent on Cell Type, Stage, and Repair Pathway 212.7.2 Delivery 212.7.3 Emerging Safety Concerns with Editing Platforms 242.7.4 Editing Products are Reliant on the Target Cells Cycle Stage and DNA Repair Machinery 272.7.5 Advantages of Gene Editing over Gene Transfer 282.7.6 Integration into Safe Harbor Sites 282.7.7 The Increasing Complexity of Gene Therapy 302.7.8 Summary of In Vivo Gene Therapy 313 Gene Therapy Near Term Product Pipeline 333.1 Leber Congenital Amaurosis 333.1.1 Unmet Need 333.1.2 Molecular Genetics 333.1.3 Luxturna (Voretigene neparvovec) 333.1.4 Editas Medicine: EDIT-101 353.1.5 Trial Design 363.1.6 EDIT-101 and Off-Target Effects 373.1.7 The Potential Advantage of EDIT-101 is the Longevity of its Therapeutic Effect 373.1.8 Summary LCA 383.2 Choroideremia 383.3 Hurler Syndrome (MPS I) 393.3.1 Key Clinical Studies 403.3.2 Regenex: RGX-111 403.3.3 Sangamo Therapeutics: SB-318 403.4 Hunter Syndrome (MPS II) 413.4.1 Unmet Need 413.4.2 Sangamo Therapeutics: SB-913 413.4.3 Immusoft Corporation: Cell Therapy 433.5 Sanfilippo Syndrome (MPS III) 433.5.1 Lysogene: LYS-SAF302 433.6 Summary MPS Disorders 443.7 Hemophilia 443.7.1 Hemophilia A 463.7.2 Summary Hemophilia A 503.7.3 Hemophilia B 513.7.4 Summary Hemophilia B 533.8 Hemoglobinopathies 543.8.1 Beta Thalassemia: Unmet Need 543.8.2 Beta Thalassemia: Molecular Genetics 553.8.3 Sickle Cell Disease: Unmet Need 563.8.4 Sickle Cell Disease: Molecular Genetics 563.9 Cellular Therapies for Hemoglobinopathies 573.9.1 Blue Bird Bio: BB-305 (LentiGlobin) 573.9.2 Sangamo: ST-400 603.9.3 CRISPR Therapeutics: CTX-001 613.9.4 Summary: Cellular Therapies for Hemoglobinopathies 623.10 Duchenne Muscular Dystrophy 633.10.1 Unmet Need 633.10.2 Molecular Genetics 633.10.3 ExonDys 51 Sarepta Therapeutics 643.10.4 Solid BioSciences: SGT-001 663.10.5 Exonics Therapeutics: CRISPR Approach 673.10.6 Summary Duchenne Muscular Dystrophy 684 Competitive Landscape 694.1 Regulatory Considerations for Developing Gene Therapy Products 694.1.1 Product Characteristics 694.1.2 Clinical Study Design for Gene Therapy Products 694.1.3 Disease specific guidance 704.1.4 Reimbursement and Payment 714.1.5 Summary Regulatory Considerations 724.2 Intellectual Property CRISPR/Cas 724.2.1 Licensing, Exploitation, and MPEG Pool 744.3 Company Analysis: Gene Editing Companies 754.3.1 Sangamo Therapeutics 754.3.2 CRISPR Therapeutics 794.3.3 Casebia Therapeutics 814.3.4 Editas Medicine 824.3.5 Intellia Therapeutics 844.3.6 Homology Medicines 864.4 Company Analysis: Pharma 874.4.1 Amgen 874.4.2 Gilead Sciences 874.4.3 Novartis 874.4.4 Sanofi 884.4.5 GlaxoSmithKline 884.4.6 Pfizer 885 Appendix 895.1 References 895.2 Report Methodology 98

and more

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read the original:
Current research: 2020 Emerging Gene Therapies Market Report - WhaTech Technology and Markets News

SALT LAKE CITY, July 07, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today two recent publications validating the polygenic risk score (PRS) component of Myriad’s breast cancer risk stratification tool riskScore®. The publications clinically validate both the ability of the PRS component of riskScore to predict breast cancer risk in asymptomatic women and modify risk estimations for patients identified with pathogenic mutations.

Historically we’ve considered breast cancer risk most significant for women diagnosed with pathogenic mutations in hereditary cancer genes. These studies demonstrate clearly that other genetic factors evaluated through Myriad’s riskScore test can dramatically alter breast cancer risk both independent of, and in combination with, gene mutations,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. This information can dramatically change patient clinical management and Myriad is currently working diligently to provide access to this important information for all women.”

The first study published in JCO Precision Oncology described the PRS component of riskScore in over 150,000 women. It showed that independent of other hereditary breast cancer gene mutations (e.g., BRCA1), Myriad’s polygenic risk score can add great value and precision to breast cancer risk estimates. The PRS was highly associated with breast cancer risk with an odds ratio of 1.47 (95% confidence interval 1.45 to 1.49) per unit standard deviation in the PRS. This translated to women in the top PRS percentile having a three-fold higher risk of breast cancer than an average risk patient.

The second study published in the Journal of the American Medical AssociationNetwork Open demonstrates the ability of Myriad’s polygenic risk score to improve breast cancer risk stratification in women diagnosed with pathogenic mutations in common breast cancer genes. The study evaluated over 150,000 patients and approximately 10,000 patients who were carriers of pathogenic mutations in the BRCA1, BRCA2, CHEK2, ATM and PALB2 genes who were tested at Myriad. The study demonstrated that patients with high penetrant genes such as BRCA1 and BRCA2 did not warrant changes in clinical management; however, breast cancer risks in patients with moderate penetrant genes such as CHEK2, ATM, and PALB2 could vary significantly, warranting different clinical management considerations. For example, patients with a PALB2 mutation historically have been assessed to have an approximately 50 percent lifetime risk for breast cancer. However, after incorporating the data from Myriad’s 86 single nucleotide polymporphism (SNP) riskScore test, patient risks varied between 26 percent to 79 percent (see Graph 1 below).

To view Graph 1: PRS Significantly Modifies Lifetime Breast Cancer Risk in Mutation Carriers please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/11ac3a62-dd7e-417a-9f08-a3a3110e01db

These are some of the largest polygenic risk score studies ever published. Patient medical management can vary dramatically depending on where patients with and without pathogenic mutations fall within the risk spectrum,” said Thomas P. Slavin M.D., senior vice president for Medical Affairs in Oncology at Myriad Genetic Laboratories. This information will help empower patients and clinicians to make more informed decisions based upon the most precise breast cancer risk estimates availiable.”

About riskScore® riskScore is a new clinically validated personalized medicine tool that enhances Myriad’s myRisk® Hereditary Cancer test. riskScore helps to further predict a women’s lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from more than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was prospectively validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to providing access to this important information for all women; and the Company’s strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Graph 1

PRS Significantly Modifies Lifetime Breast Cancer Risk in Mutation Carriers

See original here:
Myriad Announces New Studies Validating the Ability of Myriad's riskScore Test to Modify Breast Cancer Risk Prediction | 2020-07-07 | Press Releases -...

STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences Inc. (NASDAQ: APDN) (Applied DNA or the Company) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announced the formation of a wholly-owned subsidiary, Applied DNA Clinical Labs, LLC (ADCL), dedicated to the commercial development of its tests in Virology, for the detection of COVID-19, and in Oncology, for the detection and enumeration of invasive Circulating Tumor Cells (iCTCs). With the formation of ADCL, the Company is executing on a strategy to expand its market reach through value-added services complementary to a growing portfolio of diagnostic assays attractive to a broader number of qualified labs. ADCL allows Applied DNA to be a direct beneficiary of its own diagnostics development beyond the sales of kits to qualified laboratories, and provides the clinical sampling framework necessary to obtain the data required by State and Federal regulatory authorities to develop and improve diagnostics and vaccines in the face of a pandemic with rapidly shifting genetics and infectious behavior.

In mid-May, Applied DNA received Emergency Use Authorization (EUA) for a high sensitivity, high-throughput complex molecular test for SARS-CoV-2, the coronavirus that causes COVID-19. The Linea COVID-19 SARS-CoV-2 Assay Kit is a real-time polymerase chain reaction (RT-PCR) test for the qualitative detection of SARS-CoV-2 RNA in respiratory specimens. It provides a high-throughput solution to help laboratories address the urgent need for patient testing during the Coronavirus pandemic.

The Company also announced that the amendment of its EUA was approved by FDA to include extraction and concentration of the viral RNA by a magnetic method of nucleic acid extraction that lends itself easily to high throughput scaling with robotics and diversifies the two extraction methods already covered by the existing EUA. A series of EUA amendments are planned to introduce automation for increased throughput and accuracy, gain approval for additional RNA extraction methods and PCR devices to expand the footprint where our EUA assay can be used, develop point-of-care testing and simplify sample acquisition from patients.

Commenting on the amendment, Dr. James Hayward, president and CEO of Applied DNA, said, We are extremely grateful to our collaborators at Stony Brook University Hospital and to the FDA for their guidance during the development and validation of our Linea COVID-19 Assay Kit. Our goal is to service the COVID-19 patient community and their families, and to facilitate the reopening of universities and businesses with reliable, well-tested science. The demand for COVID testing is diverse, from asymptomatic patients and those in the early stages of disease, to the commercial imperative to operate.

The Company believes that as the demand for testing grows and diversifies, the existing approval of the Companys Linea COVID-19 Assay Kit for use with anterior nasal swabs will facilitate uptake by certified testing labs. As opposed to nasopharyngeal swabs, anterior nasal swabs only enter less than 1 inch into the nose, allowing for sampling with minimal irritation or discomfort. Additionally, anterior nasal swabs may be self-collected at a healthcare location or collected by a healthcare worker.

Dr. Hayward continued, With anterior nasal swabs, we believe patient compliance is not an issue. This is a simple approach to early testing, repetitive testing if begun early in infection, or high-frequency testing, such as in schools, universities, government office, and companies struggling with reopening. When combined with our high-sensitivity and high-throughput Linea COVID-19 Assay Kit, we believe the combined platform to be well suited to combat both the healthcare and economic challenges of the pandemic.

ADCL, the Companys new subsidiary was formed to enable clinical testing of patient specimens using methods developed by the Companys research teams. Access to clinical specimens will also facilitate more rapid development of improvements and new assays. All of these continuous improvements are designed to help drive sales to other approved testing labs.

ADCL was also formed to facilitate the use and development of the Companys Liquid Biopsy platform for detecting iCTCs in the blood of cancer patients, far simpler and safer than surgical or needle biopsies, and is already in use under contract in a Phase III clinical trial of a promising drug for the treatment of Stage IV pancreatic cancer. The trial involves 3,000 samples and the quantification of metastatic cancer cells in the blood. Dr. Hayward continued, Eventually, with the utility of ADCL, we plan to seek regulatory approval for our iCTC assay and add it to the tools used in modern oncology to ensure better patient outcomes.

The Company has obtained its Permanent Facility Identifier for ADCL, has hired a New York State Licensed Clinical Laboratory Director for Oncology and Virology and Certified Laboratory Scientists, and has applied for a license from the New York State Department of Health.

There can be no assurance that this license will be obtained, or that FDA will maintain the Emergency Declaration that enabled the EUA program for COVID-19 diagnostics. There can be no assurance that the Company will obtain approved 510K status (or other necessary regulatory approval) for its COVID-19 In Vitro Diagnostics in the event that the Emergency Declaration is lifted. In addition, the Companys iCTC assay is currently limited to RUO (Research Use Only), and there can be no assurance that the Company will obtain the necessary regularly approval for its iCTC assay to expand its use outside of RUO limitations.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Companys common stock is listed on NASDAQ under ticker symbol APDN, and its publicly traded warrants are listed on OTC under ticker symbol APPDW. Applied DNA is a member of the Russell Microcap Index.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be forward-looking in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNAs future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the possibility of a failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNAs assets, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNAs diagnostic candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to U.S. FDA, equivalent foreign regulatory agencies or New York State Department of Health, the unknown limited duration of any Emergency Use Authorization (EUA) approval from U.S. FDA, disruptions in the supply of raw materials and supplies, and various other factors detailed from time to time in Applied DNAs SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and our subsequent quarterly reports on Form 10-Q filed on February 6, 2020 and May 14, 2020, and other reports we file with the SEC, which are available at http://www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005245/en/

See the original post here:
Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea COVID-19 Assay Kit and Expands Utility with Successful EUA...

SEATTLE, July 8, 2020 /PRNewswire/ --Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market.

"I am delighted that Janet Rea will join our team at AVM Biotechnology as the Chief Operating Officer. Having worked with Janet during a pivotal time at Protein Sciences while pursuing Flublok FDA approval," said Dr. Manon Cox, AVM Biotechnology's Executive Board Member, "I know that her passion for quality and her tremendousexperience in the transition from development into commercialization is exactly what we need at this crucial time at AVM now that our lead product is moving into the clinic."

Janet R. Rea, MSPH, RAC, brings over 35 years of industry leadership experience in clinical development through commercialization in biologics and small molecules, with focus on oncology, infectious diseases, orphan and rare diseases. She obtained her B.S. in microbiology and M.S. in Public Health from the University of Washington. Her career in the healthcare industry began with then-American Hospital Supply Corporation (now Baxter), followed by Genetic Systems. Ms. Rea was an early employee of Seattle-based Immunex Corporation, where she played a key role in the company's first licensed product, Leukine. She held positions with increasing levels of responsibility with MDS Pharma and Targeted Genetics, as well as executive positions with AVI BioPharma (now Sarepta), Poniard Pharmaceuticals and Protein Sciences Corporation (acquired by Sanofi), and Therapeutic Proteins International. Most recently, she was SVP of Regulatory, Quality and Clinical Affairs at Atossa Therapeutics (Genetics) with focus on breast cancer and COVID-19 therapy development. She has also operated a consulting practice to both small and large organizations and has lectured at the University of Washington for the Biomedical Regulatory Affairs Certificate and Master's Program, where she also served as a parttime Assistant Clinical Professor for two years.Ms. Rea will serve as a non-voting member of AVM's Board of Directors.

"I am thrilled and honored to be joining AVM Biotechnology and look forward to working with this distinguished team to make new therapies available," Ms. Rea said. Named one of the "10 Best Biotech & Pharma Companies to Keep an Eye On in 2019" by Mirror Review, AVM Biotechnology was founded in 2008 by Dr. Theresa Deisher, Ph.D. With over 30 years of successful pharmaceutical research experience and holding over 47 patents, Dr. Deisher leads a team of scientists dedicated to changing the meaning of a diagnosis of cancer, autoimmunity, or chronic infectious disease for patients and their loved ones. In April 2020, AVM received FDA permission to begin clinical trials to test its lead molecule AVM0703 for treatment of relapsed/refractory lymphoid malignancies, and is filing for FDA approval to begin clinical trials in treating COVID-19 and influenza induced ARDS. AVM's passion is to deliver drugs that work rapidly and that are safe, effective, and affordable to treat serious worldwide illnesses such as cancer, autoimmunity, and life-altering infectious disease. AVM develops products that improve outcomes without additional suffering because side effects from treatments of cancers or infections should never be worse than the diseases themselves. The addition of Janet Rea to the AVM team, which includes a global group of experienced biotech advisors, makes AVM well positioned to bring AVM0703 to market in treating multiple conditions.

Contact Jena Dalpez Jdalpez@AVMBiotech.com

ALL INFORMATION CONTAINED HEREIN HAS BEEN PROVIDED BY THE COMPANY AND NO OTHER PARTY HAS INDEPENDENTLY VERIFIED ANY OF THE INFORMATION, INCLUDING THE FINANCIAL ESTIMATES AND PROJECTIONS CONTAINED HEREIN. SOME OF THE STATEMENTS IN THE MEMORANDUM ARE "FORWARD-LOOKING STATEMENTS." THESE FORWARD-LOOKING STATEMENTS INCLUDE, BUT ARE NOT LIMITED TO, STATEMENTS ABOUT THE COMPANY'S PLANS, OBJECTIVES, EXPECTATIONS AND INTENTIONS AND OTHER STATEMENTS CONTAINED IN THE MEMORANDUM THAT ARE NOT HISTORICAL FACTS. WHEN USED IN THIS MEMORANDUM, THE WORDS "ASSUMES," "ANTICIPATES," "BELIEVES," "CONTINUE," "COULD," "EXPECTS," "FORECASTS," "INTENDS," "MAY," "PLANS," "SEEKS," "SHOULD," OR "WILL" OR THE NEGATIVE OF THESE TERMS OR SIMILAR EXPRESSIONS ARE GENERALLY INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. BECAUSE THESE FORWARD-LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES, THERE ARE IMPORTANT FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS, INCLUDING THE COMPANY'S PLANS, OBJECTIVES, EXPECTATIONS AND INTENTIONS AND OTHER FACTORS DISCUSSED UNDER "RISK FACTORS" SUCH STATEMENTS, ESTIMATES AND PROJECTIONS REFLECT VARIOUS ASSUMPTIONS OF THE COMPANY THAT MAY OR MAY NOT PROVE TO BE CORRECT. AND NO REPRESENTATION IS MADE AND NO ASSURANCE CAN BE GIVEN THAT THE COMPANY CAN OR WILL ATTAIN SUCH RESULTS.

See more here:
AVM Biotechnology Expands Executive Team in Preparation for Oncology & COVID-19 Clinical Trials, Appoints Janet R. Rea, MSPH, Chief Operating...

Biotechnologys game-changing role as a catalyst to reboot the economy and build a more sustainable future will be the focus of a summit co-hosted by The University of Manchester.

The panel debate and live Q&A is entitled Biotechnology: The Catalyst for a Sustainable Future and will feature leading experts from the prestigious Manchester Institute of Biotechnology who will be joined by national policy-makers and influencers.

The virtual event will be held on Wednesday, July 15, 3-4pm and the discussion will coincide with a special Spotlight supplement focusing on the UKs world-leading biotechnology capability to be published in the latest edition of the New Statesman. Hosted in partnership with the magazine the expert panel will be made up of:

George Freeman, MP, and former Minister of Life Sciences

Professor Rob Field, Director of the Manchester Institute of Biotechnology

Yvonne Armitage Chair of the External Advisory Board for Future Biomanufacturing Research

Professor Lionel Clarke OBE, Co-Chair of the UK Engineering Biology Leadership Council

Industrial Biotechnology (IB) is the term that describes the application of natures catalysts ie enzymes and other biological systems to sustainably produce chemicals, materials and energy says Professor Rob Field, Director of the Manchester Institute of Biotechnology (MIB).

Using the latest developments in biotechnology, and by collaborating with industry, it will be possible to produce medicines, plastics and fuels that are not are not sourced from carbon-generating fossil fuels.

Themes that will be put under the spotlight at the live streamed debate will include the potential capability of biotechnology to meet the global grand challenges and how might the COVID-19 crisis act as a catalyst to accelerate the adoption of biotechnology by society.

Sustainable development is one of the biggest challenges facing society and industry today as we look to meet todays energy, food and manufacturing needs without exhausting the Earths resources, explained Professor Field.

Biotechnology could provide the catalyst for revolutionary change and help us build a better more sustainable future.

COVID-19 has shown science at its best agile yet focused, collaborative while competitive. We can learn from the experience to develop a more resilient and sustainable world. Biotechnology has a large part to play in supporting a clean growth recovery.

Our panel discussion and the special edition of the New Statesmans Spotlight which supports this talk will reveal just of how biotechnology could help support a sustainable re-booting of the economy.

Register to tune in to this online event at 3pm on Wednesday, July 15, and receive joining information closer to the date. Spaces are available on a first come, first serve basis. Registration details here: https://www.newstatesman.com/2020/06/new-statesman-and-mib-webinar-biotechnology-catalyst-sustainable-future

###

View post:
Could biotechnology be the vital catalyst to deliver a green economic recovery? (Study) - Tdnews

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), http://www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that Dr. Elemer Piros has rejoined the firms healthcare research team, as Managing Director, Senior Research Analyst covering biotechnology. His research coverage is expected to include SMID cap Biotechnology companies across the therapeutic space, with an initial focus on companies developing novel drugs for CNS, hematology, ophthalmology and liver indications.

Prior to joining ROTH, Dr. Piros was a senior biotechnology analyst at Cantor Fitzgerald and ROTH between 2015 and 2019. Previously, Dr. Piros was the interim CEO of eMMUNITY, Inc, an immunotherapy startup company. Prior to the position at eMMUNITY, he was a publishing senior biotechnology analyst at Rodman & Renshaw and Burrill Securities, covering 80 total companies at various points of time, including companies developing products for CNS disorders, inflammation and the diagnosis and treatment of cancer.

Dr. Piros was a buyside biotechnology analyst at Spear, Leeds & Kellogg, a wholly owned subsidiary of Goldman Sachs. From 1990 to 2000, he conducted academic research in the field of neuroscience, focusing on understanding the molecular mechanism of communication in the nervous system.

Dr. Piros was ranked as the #1 Biotechnology analyst by the Wall Street Journal in 2006 and by the Financial Times in 2010, both based on stock portfolio performance.

Jeff Martin, CFA - Director of Research, commented, ROTH continues to invest in biotechnology research talent to enhance the strength of our Healthcare platform. Im pleased to welcome back Elemer to our thought-leading biotechnology research team. His strong academic background combined with his biotechnology industry experience will undoubtedly serve our clients well.

Dr. Piros commented, I am delighted to rejoin ROTH, a highly regarded investment bank with a strong track record in healthcare. I am very impressed by the quality and depth of the ROTH research portfolio. My goal is to provide a significant contribution by analyzing companies with cutting-edge medical research and translating science and clinical findings to actionable investment recommendations.

We are excited to have Elemer back on our healthcare research team, said Byron Roth, CEO of ROTH. His addition further demonstrates our unwavering commitment to the life sciences sector. Im confident that Elemers expertise in biotechnology will enhance our ability to continue to build upon our over 10-year track record of success in assisting both companies and investors in the healthcare sector.

About Roth Capital Partners, LLC:

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.

Headquartered in Newport Beach, Calif., ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S. For more information on ROTH, please visit http://www.roth.com.

Follow this link:
ROTH Capital Partners Announces the Addition of Elemer Piros, Ph.D. to its Healthcare Research Team - Business Wire

New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Nanoparticles in Biotechnology and Pharmaceuticals Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Nanoparticles in Biotechnology and Pharmaceuticals market.

The research study includes the latest updates about the COVID-19 impact on the Nanoparticles in Biotechnology and Pharmaceuticals sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Nanoparticles in Biotechnology and Pharmaceuticals manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Nanoparticles in Biotechnology and Pharmaceuticals market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Nanoparticles in Biotechnology and Pharmaceuticals sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Nanoparticles in Biotechnology and Pharmaceuticals, the report covers-

Bytype1

In Market Segmentation by Applications of the Nanoparticles in Biotechnology and Pharmaceuticals, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=3WN&utm_medium=003

The Nanoparticles in Biotechnology and Pharmaceuticals market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Nanoparticles in Biotechnology and Pharmaceuticals market.

This study analyzes the growth of Nanoparticles in Biotechnology and Pharmaceuticals based on the present, past and futuristic data and will render complete information about the Nanoparticles in Biotechnology and Pharmaceuticals industry to the market-leading industry players that will guide the direction of the Nanoparticles in Biotechnology and Pharmaceuticals market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Nanoparticles in Biotechnology and Pharmaceuticals market. Additionally, it includes a share of each segment of the Nanoparticles in Biotechnology and Pharmaceuticals market, giving methodical information about types and applications of the market.

Reasons for Buying Nanoparticles in Biotechnology and Pharmaceuticals Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Nanoparticles in Biotechnology and Pharmaceuticals market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=3WN&utm_medium=003

In the end, the Nanoparticles in Biotechnology and Pharmaceuticals market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Nanoparticles in Biotechnology and Pharmaceuticals market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

More here:
Nanoparticles in Biotechnology and Pharmaceuticals Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 -...

Akero Therapeutics Inc (AKRO) is around the top of the Biotechnology industry according to InvestorsObserver. AKRO received an overall rating of 69, which means that it scores higher than 69 percent of all stocks. Akero Therapeutics Inc also achieved a score of 78 in the Biotechnology industry, putting it above 78 percent of Biotechnology stocks. Biotechnology is ranked 11 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Akero Therapeutics Inc (AKRO) stock is trading at $37.79 as of 10:20 AM on Wednesday, Jul 8, a rise of $0.73, or 1.97% from the previous closing price of $37.06. The stock has traded between $37.61 and $41.00 so far today. Volume today is above average. So far 607,617 shares have traded compared to average volume of 380,338 shares.

To screen for more stocks like AKRO click here.

The rest is here:
Is Akero Therapeutics Inc (AKRO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Agricultural Biotechnology Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Agricultural Biotechnology market.

The research study includes the latest updates about the COVID-19 impact on the Agricultural Biotechnology sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Agricultural Biotechnology manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Agricultural Biotechnology market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Agricultural Biotechnology sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Agricultural Biotechnology, the report covers-

Bytype1

In Market Segmentation by Applications of the Agricultural Biotechnology, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=35624&utm_source=3WN&utm_medium=007

The Agricultural Biotechnology market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Agricultural Biotechnology market.

This study analyzes the growth of Agricultural Biotechnology based on the present, past and futuristic data and will render complete information about the Agricultural Biotechnology industry to the market-leading industry players that will guide the direction of the Agricultural Biotechnology market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Agricultural Biotechnology market. Additionally, it includes a share of each segment of the Agricultural Biotechnology market, giving methodical information about types and applications of the market.

Reasons for Buying Agricultural Biotechnology Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Agricultural Biotechnology market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/agricultural-biotechnology-market/?utm_source=3WN&utm_medium=007

In the end, the Agricultural Biotechnology market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Agricultural Biotechnology market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

See the original post:
Agricultural Biotechnology Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 - 3rd Watch News

The 69 rating InvestorsObserver gives to Akero Therapeutics Inc (AKRO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 78 percent of stocks in the Biotechnology industry, AKROs 69 overall rating means the stock scores better than 69 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Akero Therapeutics Inc (AKRO) stock is trading at $37.69 as of 11:28 AM on Wednesday, Jul 8, a rise of $0.63, or 1.7% from the previous closing price of $37.06. Volume today is above average. So far 935,742 shares have traded compared to average volume of 380,338 shares. The stock has traded between $37.50 and $41.00 so far today.

To see the top 5 stocks in Biotechnology click here.

View post:
Is Akero Therapeutics Inc (AKRO) Stock a Good Buy in Biotechnology - InvestorsObserver

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on development of first-in-class drugs, announced today that encouraging preclinical results supporting newly-identified immunogenic effects of the companys lead product candidate, investigational THIO (6-thio-dG), the only telomere-by-telomerase targeting agent in development for the treatment of cancer, has been published in Cancer Cell, a renowned peer-reviewed scientific journal covering major advances in cancer research. The manuscript entitled: Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity, Mender et al., is now featured online and will also be published in the September 2020 edition of Cancer Cell, Volume 38, pages 1-12.

Telomerase is the enzyme responsible for the maintenance of telomeres. While inactive in most normal cells, telomerase is activated in the majority of cancer cells, making it an attractive target for cancer therapy. Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage. The latest preclinical data showed this is complemented by an immunogenic effect, which may allow for more durable outcomes when used sequentially with immunotherapy. THIOs activity was shown to be cancer-specific in tumor types with active telomerase. Since up to 35 million patients have telomerase-positive cancers, MAIA Biotech believes these results suggest that THIO holds significant potential to treat large patient populations across many types of cancers.

In these preclinical studies published in Cancer Cell, investigators demonstrated that THIO leads to tumor regression through induction of innate and adaptive host immune system responses. THIO was shown to be directly incorporated into telomeres by telomerase, where it rapidly induced telomeric DNA damage responses, which is selective to telomerase-positive TERT(+) cancer cells without affecting normal telomerase-silent cells. The findings also indicated that THIO induces DNA-mediated innate sensing and activation of immune responses in a host cGAS/STING-dependent manner, leading to improved anti-tumor efficacy. Low doses of THIO, followed by anti-PD-L1 therapy, completely eliminated advanced tumors in preclinical models and produced cancer cell specific immune memory where the immune system continued to be active against the cancer cells after extended periods of time with no additional treatment. These results are significant as they demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining telomere-targeted therapy with immunotherapy.

We believe THIO has the potential to transform the immuno-oncology landscape and change the cancer treatment paradigm, and these most recent findings provide a strong rationale for combining telomere-targeted therapy with immunotherapy, stated Vlad Vitoc, MD, MAIAs Chief Executive Officer and President. We believe the publication of these unprecedented immunogenic effects of THIO in Cancer Cell provides additional validation for this innovative program. We are highly encouraged by these promising findings of tumor elimination, cancer specific immune responses, and stimulation of immune memory, which build upon prior positive preclinical results. These findings provide further support for the companys plans to advance THIO into Phase 1 clinical studies in 2021.

About THIO

THIO (6-thio-dG) is a small molecule in preclinical development and is the only telomere-by-telomerase targeting agent currently in development. THIO is designed to selectively kill cancer cells by modifying telomeric DNA structure and function utilizing telomerase. Telomerase is present in >85% of human cancers and contributes significantly to proliferation and immortality of cancer cells. THIO is recognized by telomerase and incorporated into telomeres selectively in cancer cells. Once incorporated, it compromises the telomere structure and function, leading to uncapping of the chromosome ends and thus resulting in rapid tumor cell death. In preclinical studies, this rapid cancer cell death occurred without impacting normal cells. THIO is investigational and has not been approved for any use anywhere in the world.

About Cancer Cell

Cancer Cell provides a high-profile forum to promote major advances in cancer research and oncology. The primary criterion for considering manuscripts is whether the studies provide major advances into answering important questions relevant to naturally occurring cancers. Cancer Cell is also interested in publishing clinical investigations, in particular those that lead to establishing new paradigms in the treatment, diagnosis, or prevention of cancers; those that provide important insights into cancer biology beyond what has been revealed by preclinical studies; and those that are mechanism-based proof-of-principle clinical studies. For more information, please visit http://www.cell.com/cancer-cell or follow the journal on Twitter: @Cancer_Cell.

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. MAIAs business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure. Drug candidates include (i) THIO, a telomere-by-telomerase targeting agent in preclinical development for the treatment of telomerase positive cancer cells; (ii) GMC1, a FKBP52 co-chaperone-inhibitor being evaluated for prostate cancer and breast cancer; and (iii) MJC13 is a drug candidate with a potentially novel mode of action targeting androgen receptor (AR) inhibition that is important in prostate and breast cancers. MAIA is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into clinical trials. For more information, please visit http://www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industrys actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as may, might, will, should, could, expect, plan, anticipate, believe, estimate, project, intend, future, potential or continue, and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, MAIA, Company, we, our, and us refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005271/en/

See original here:
MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO -...

The Pharmaceutical and Biotechnology Machines Market Analysis to 2027 is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of pharmaceutical and biotechnology machines market with detailed market segmentation by of product and end user/application. The pharmaceutical and biotechnology machines market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in pharmaceutical and biotechnology machines market and offers key trends and opportunities in the market.

Some of the key players profiled in the study are Air Liquide, Atlas Copco AB, Beijing Orient, Linde Healthcare, Messer Group, Nanning Lantian, Shenwei Medical, Shenzhen Gaofa, Sicgil India Limited, SOL Group, Taiyo Nippon Sanso, etc.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00011795/

What is Pharmaceutical and Biotechnology Machines Market?

The biotechnology machine is for process Separations. Also, process-scale separation systems, mainly high-volume chromatography systems, are among the most crucial biotechnology machine in the modern biopharmaceutical industry. Its applications of process chromatography include recombinant protein purification. Pharmaceutical biotechnology refers to the use of biotechnology for manufacturing drugs, gene therapy as well as gene testing. This is done by manipulating and modifying organisms, usually at the molecular level.

The pharmaceutical and biotechnology machines market is propelling due to advancement of technology and rising geriatric population. However, the high cost of devices, stringent regulations, and lack of skilled personnel hamper the market growth.

The pharmaceutical and biotechnology machines market is segmented on the basis of product and end user/application. Based on product, the market is segmented as oxygen, nitrous oxide, medical air and others(nitrogen, carbon dioxide and helium). On the basis of end user/application, the market is categorized as hospitals (labs and clinics), home healthcare, universities/research institutions and pharmaceutical and biotechnology industries.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted Price @ https://www.theinsightpartners.com/discount/TIPRE00011795/

Key questions answered by this report:

Our reports will help clients solve the following issues:

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00011795/

Pharmaceutical and Biotechnology Machines Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Read the original:
Pharmaceutical and Biotechnology Machines Market: How the Business Will Grow in 2027? - Apsters News

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Biotechnology Separation Systems Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Biotechnology Separation Systems market.

The research study includes the latest updates about the COVID-19 impact on the Biotechnology Separation Systems sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Biotechnology Separation Systems manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=207653&utm_source=3WN&utm_medium=888

The Biotechnology Separation Systems market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Biotechnology Separation Systems market.

This study analyzes the growth of Biotechnology Separation Systems based on the present, past and futuristic data and will render complete information about the Biotechnology Separation Systems industry to the market-leading industry players that will guide the direction of the Biotechnology Separation Systems market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Biotechnology Separation Systems market. Additionally, it includes a share of each segment of the Biotechnology Separation Systems market, giving methodical information about types and applications of the market.

Reasons for Buying Biotechnology Separation Systems Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Biotechnology Separation Systems market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=207653&utm_source=3WN&utm_medium=888

In the end, the Biotechnology Separation Systems market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Biotechnology Separation Systems market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Hernia Repair Devices Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Hexagon Shaped Tables Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Hidden Framing Glass Curtain Wall Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

High Carbon Spring Steel Wire Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

High Frequency Solar Inverter Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the rest here:
Cosmetics Implants Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

The globalwhite biotechnology marketis highly consolidated, as key players are holding 71% share in the global market, reports Transparency Market Research. Prominent players in the market are investing heavily in research and development activities in order to produce effective and better results. These players are also investing in mergers and acquisition, collaboration, partnership, and innovation to get a stronger hold in the market. Apart from key players, few small and medium players are also engaging in these strategies mainly to maintain their position in the market. In this report, researchers have analyzed few leading players including Cargill Inc., Archer Daniels Midland Company, DuPont, BASF SE, and Novozymes.

As per TMRs report, the global white biotechnology market is expected to rise at 4.50% CAGR over the projected tenure between 2016 and 2024. If the market progresses at this rate, the markets revenue is likely to reach US$262.3 bn by the end of 2024. In 2015, the market earned US$ US$178.1 bn.

On the basis of product, the demand in the biofuel segment is high. In 2015, this segment held 31.16% share in the global white biotechnology market. Over the forecast period, this segment is likely to maintain its position. In terms of application, others segment is expected to lead the global market. On the regional front, North America to hold maximum share in the global white biotechnology market. Increasing funding from government for research and development activities in the field of white biotechnology has fueled demand in North America white biotechnology market

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) :https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2317

Increasing Government Support to Benefit Growth in White Biotechnology

Rising government initiatives to promote white biotechnology is one of the major factor driving demand in the global white biotechnology market. In addition, white technology is also environment friendly and produces low waste by using efficient methods of production. The white biotechnology cannot be compared with oil and crop prices, as the prices of this technology keep on fluctuating rapidly. Furthermore, growing need from various consumer industries such as consumer goods and automotive to meet sustainability targets is projected to augment technology demand over the projected period.

Adding further to the growth factors, increasing government support to growth of white biotechnology through research and development activities and schemes are also expected to expand growth opportunities for the global white biotechnology market. Moreover, increasing demand for green chemicals in developed regions who are ready to pay higher prices for renewable products will further accelerate demand in this market.

REQUEST FOR COVID19 IMPACT ANALYSIS https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2317

Deteriorating Fertility of Agricultural Lands Might Hamper Growth in White Biotechnology Market

The key challenge that might hamper the growth in the global white biotechnology market includes deteriorating fertility of agricultural lands. This takes place due to over and misuse of fertilizers upon crops that resulted in depleting fertility from agricultural lands. Due to over utilization of fertilizers, the prices of bio-crops have been fluctuated, as there was uncertainty of production yield of bio-crops. Moreover, use of traditional foods and fuels by customers is also expected to hamper growth in the global white biotechnology market.

The study presented here is based on a report by Transparency Market Research (TMR) titled White Biotechnology Market (Product Biochemical, Biofuel, Biomaterial, Bioproduct; Application Food and Feed, Pharmaceuticals, Pulp and Paper, Textile, Energy; Feedstock Grains and Starch Crops, Agricultural Residues, Food Waste, Forestry Material, and Animal) Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 2024.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

The global white biotechnology market is segmented based on:

Product

Application

Feedstock

Regional

More Trending Reports by Transparency Market Research 1.https://www.prnewswire.com/news-releases/global-chronic-obstructive-pulmonary-disease-copd-treatment-market-to-reach-us-26-2-bn-in-2027-drug-makers-focus-on-combination-therapies-transparency-market-research-301011476.html

2.https://www.biospace.com/article/peptide-therapeutics-market-to-experience-extensive-growth-thanks-to-rising-demands-for-improved-healthcare/

Read the rest here:
Analysis of Potential Impact of COVID-19 on White Biotechnology Market - Cole of Duty

WUHAN, China, July 7, 2020 /PRNewswire/ -- Hubei Soundny Biotechnology ("Soundny" or the "Company"), a leading biotechnology company dedicated to developing cancer treatments, has announced the publication of its latest findings on cholangiocarcinoma in Nature Biomedical Engineering, a Nature publication.

The research highlights a drug-loaded microvesicles tumor therapy for cholangiocarcinoma, approved for clinical use which has shown significant efficacy and safety in the treatment of cholangiocarcinoma.

Data shows that the United States sees about 10,000 new cholangiocarcinoma cases annually, while the incidence rate in Asia is about 3 in 10,000. China is one of the countries with the highest incidence rate of cholangiocarcinoma in the world.

"Despite this high incidence rate, there's still no standardized treatment plan in place for cholangiocarcinoma", said Zhang Hui, Co-author of the article and a Director at Nankai Hospital. "Experts prioritize surgical excision in the treatment of cholangiocarcinoma. However, this is not beneficial as the early symptoms can be hard to spot, which means most patients tend to go to the doctors during the middle or late stages of cancer development. Only 20% of these patients will have the opportunity for radical surgery. This discovery offers the other 80% some hope in fighting the disease," he added.

Patients with middle or late-stage onset of cholangiocarcinoma often have difficulty in finding a suitable treatment. Particularly as the anatomical spot and "shell" of the tumor tissue makes treatment difficult. Furthermore, radiotherapy and chemotherapy have been seen to be less effective in patients in the later stages of the disease.

A Drug-based Breakthrough in the Fight Against Cancer

Since 2015, Soundny has cooperated with Nankai hospital on clinical trials of drug-loaded vesicles for the treatment of cholangiocarcinoma as an alternative to radio and chemotherapy. A total of 20 patients with late-stage hilar cholangiocarcinoma were introduced and enrolled in the program. The survival time of patients at this stage of the diseases generally falls between three to six months.

The results of the study showed that around 30% of the patients entered partial remission of biliary obstruction. Approximately 50% of the patients had reduced symptoms of jaundice with improved liver function after the first treatment. The color of stool samples also changed from terracotta to standard yellow, with an extended survival period of up to 21 months.

In terms of safety, there was no significant change found in routine blood, liver and kidney tests, and no other symptoms such as abdominal pain, nausea, vomiting, were recorded.

Professor Wang said that the medicated vesicle treatment for cholangiocarcinoma had "marked a breakthrough and is expected to become a first-line treatment plan for the treatment of cholangiocarcinoma," he said.

The findings, co-published by Professor Ximo Wang and his research team at Tianjin Medical University and Soundny, titled "Methotrexate-loaded tumour-cell-derived microvesicles can relieve biliary obstruction in patients with extrahepatic cholangiocarcinoma" is to appear in the 11pm on July 6th, 2020, issue of Nature Biomedical Engineering.

About Hubei Soundny Biotechnology

Hubei Soundny Biotechnology (Soundny) is a biotechnology company specializing in the research, development, application and promotion of drug-loaded vesicle cancer treatment in China. The company holds more than 30 patents in Mainland China, Hong Kong, the United States, the European Union and Japan. It has established production and R&D lines for the discovery of treatments relating to tumors and complications including cholangiocarcinoma, lung cancer, malignant pleural effusion and malignant ascites.

View original content:http://www.prnewswire.com/news-releases/a-breakthrough-in-cancer-treatment-soundny-presents-a-new-drug-based-alternative-in-fight-against-cancer-301088857.html

SOURCE Hubei Soundny Biotechnology

Read the original post:
A Breakthrough in Cancer Treatment: Soundny Presents a New Drug-based Alternative in Fight Against Cancer - BioSpace

Vir Biotechnology, Inc. (NASDAQ:VIR) went up by 1.74% from its latest closing price when compared to the 1-year high value of $75.00 and move down -82.84%, while VIR stocks collected +5.64% of gains with the last five trading sessions. Press Release reported 17 hours ago that Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) 2 of the analysts out of 5 who provided ratings for Vir Biotechnology, Inc. stocks as a buy while 0 as overweight, 1 rated it as hold and 1 as sell. The average price we get from analysts is $32.50 which is -$6.35 below current price. VIR currently has a short float of 2.80% and public float of 99.67M with average trading volume of 1.65M shares.

VIR stocks went up by 5.64% for the week, with the monthly jump of 20.61% and a quarterly performance of 41.45%. The simple moving average for the period of the last 20 days is 7.60% for VIR stocks with the simple moving average of 62.80% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -45.31% of loss for the given period.

The stock volatility was left at 9.77%, however, within the period of a single month, the volatility rate increased by 9.02%, while the shares surge at the distance of +23.52% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +31.69% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +5.64%, in comparison to the 20-day moving average settled at $38.51. In addition, Vir Biotechnology, Inc. saw 226.20% in overturn over the period of a single year with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at Vir Biotechnology, Inc. (VIR), starting from Horn Howard, who sold 10,000 shares at the price of $40.00 back on Jul 02. After this action, Rushing now owns 207,777 shares of Vir Biotechnology, Inc., valued at $400,000 with the latest closing price.

Parrish Jay, the Chief Business Officer of Vir Biotechnology, Inc., sold 75,000 shares at the value of $37.95 during a trade that took place back on Jul 01, which means that Parrish Jay is holding 222,222 shares at the value of $2,846,310 based on the most recent closing price.

The current profitability levels are settled at -2144.35 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -62.52, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Read the original here:
Vir Biotechnology, Inc. (VIR) Plans and Analysts Expectations - The News Heater

Global Biotechnology Separation Systems Market analysis 2015-2027, is a research report that has been compiled by studying and understanding all the factors that impact the market in a positive as well as negative manner. Some of the prime factors taken into consideration are: various rudiments driving the market, future opportunities, restraints, regional analysis, various types & applications, Covid-19 impact analysis and key market players of the Biotechnology Separation Systems market. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Download Report from: https://cognitivemarketresearch.com/machinery-%26-equipment/biotechnology-separation-systems-market-report

Global Biotechnology Separation Systems Market: Product analysis: Membrane Filtration, Chromatography, Centrifuge, Electrophoresis, Flow Cytometry, Others

Global Biotechnology Separation Systems Market: Application analysis: Commercial, Scientific Research

Major Market Players with an in-depth analysis: Danaher, Thermo Fisher Scientific, BD, Merck, GE Healthcare, Agilent, Sysmex, Alfa Wassermann, Shimadzu, Sartorius Stedim Biotech, Illumina, Waters, Novasep, 3M Purification, Affymetrix, Bio Rad Laboratories, Alfa Laval, PerkinElmer, Repligen, Hitachi Koki

The research is presented in such a way that it consists of all the graphical representations, pie charts and various other diagrammatic representations of all the factors that are used for the research. Biotechnology Separation Systems market research report also provides information on how the industry is anticipated to provide a highly competitive analysis globally, revenues generated by the industry and increased competitiveness and expansions among various market players/companies.

Get A Free Sample of Biotechnology Separation Systems Market Report: https://cognitivemarketresearch.com/machinery-%26-equipment/biotechnology-separation-systems-market-report#download_report

The Biotechnology Separation Systems industry is projected in assembling information regarding dynamic approximations and also listings of a profitable progression rate annually in the expected duration according to a recent & latest study. The latest Coronavirus pandemic impact along with graphical presentations and recovery analysis is included in the Biotechnology Separation Systems research report. The research report also consists of all the latest innovations, technologies and systems implemented in the Biotechnology Separation Systems industries.

Various factors with all the necessary limitations, expenditure/cost figures, consumer behaviour, supply chain, government policies and all the information related to the market have been included in the Biotechnology Separation Systems Market report. The research report also provides light on various companies & their competitors, market size & share, revenue, forecast analysis and all the information regarding the Biotechnology Separation Systems Market.

Checkout Inquiry for Buying or Customization of Report: https://cognitivemarketresearch.com/machinery-%26-equipment/biotechnology-separation-systems-market-report#download_report.

Biotechnology Separation Systems Market research report provides an in-depth analysis of the entire market scenario starting from the basics which is the market introduction till the industry functioning and its position in the market as well as all the projects and latest introductions & implementations of various products. The research study has been assembled by understanding and combining various analysis of regions globally & companies and all necessary graphs and tables that bring the theory into an exact representation through numerical values and standard tables.

The global estimations of the market value, market information/definition, classifications of all the types & applications, overall threats & dips that can be assumed and many other factors which consist the overall market scenario and its happening globally along with the forthcoming years are compiled in the Biotechnology Separation Systems market research report. Hence this report can serve as a handbook/model for the enterprises/players interested in the Biotechnology Separation Systems Market as it consists all the information regarding the Biotechnology Separation Systems market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Biotechnology Separation Systems Market Report 2020 (Coronavirus Impact Analysis on Biotechnology Separation Systems Market)

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.(*If you have any special requirements, please let us know and we will offer you the report as you want.)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com/

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/machinery-%26-equipment/biotechnology-separation-systems-market-report

The rest is here:
GlobalBiotechnology Separation Systems Market Report 2020 Sales Forecast to Grow Negatively in Western Regio post COVID 19 Impact Analysis Updated...

The 55 rating InvestorsObserver gives to Liminal BioSciences Inc (LMNL) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 47 percent of stocks in the Biotechnology industry, LMNLs 55 overall rating means the stock scores better than 55 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Liminal BioSciences Inc (LMNL) stock is trading at $13.40 as of 11:27 AM on Tuesday, Jul 7, a decline of -$0.29, or -2.12% from the previous closing price of $13.69. The stock has traded between $13.05 and $14.70 so far today. Volume today is light. So far 67,596 shares have traded compared to average volume of 107,701 shares.

To see InvestorsObserver's Sentiment Score for Liminal BioSciences Inc click here.

Go here to see the original:
Is Liminal BioSciences Inc (LMNL) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver